Globela Pharma Private Limited

EY has successfully advised Globela Pharma Private Limited (Globela Pharma) in raising capital from Somerset Indus Capital Partners (Somerset Indus) for a minority stake. 

EY acted as the exclusive financial advisor to Globela Pharma.

Established in 2006, Globela Pharma is Surat-based company focused on offering pharma formulations and Active Pharmaceutical Ingredients (APIs) globally across multiple therapeutic areas including oncology, gastro, CVS etc.  It has presence across over 25 countries with a portfolio of over 250 product registrations, backed by DSIR-approved research and development facility. It owns and operates WHO cGMP accredited manufacturing facilities including a dedicated oncology formulations block.

Established in 2011, Somerset Indus is a healthcare focused private equity firm making private equity and equity-related investments primarily in growth-oriented healthcare companies in India. It aims to invest in healthcare delivery product and service platforms run by experienced healthcare entrepreneurs which are focused on providing quality and affordable healthcare across India, especially in the lower tier markets. Somerset Indus through its investment thesis of profitable and sustainable impact based investing has been supporting capacity build up and aims to deliver accessibility and affordability to healthcare in India with a key focus on creating a positive impact on the environment, society, and governance.